Last reviewed · How we verify
amniotic membrane
At a glance
| Generic name | amniotic membrane |
|---|---|
| Also known as | PalinGen KardiaMembrane, PalinGen Kardia XPlus Membrane |
| Sponsor | Red de Terapia Celular |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- pAF for the Treatment of Osteoarthritis (PHASE1, PHASE2)
- Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn
- A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers (NA)
- Evaluation of the Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft vs Standard of Care in the Treatment of Partial Thickness Thermal Burns (PHASE4)
- XVIE to Treat Androgenetic Alopecia (AGA) (PHASE1, PHASE2)
- Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (NA)
- Comparative Study of Decellularized Human Amniotic Membrane Hydrogel and Inverted Internal Limiting Membrane Flap in Idiopathic Large Macular Holes (NA)
- Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amniotic membrane CI brief — competitive landscape report
- amniotic membrane updates RSS · CI watch RSS
- Red de Terapia Celular portfolio CI